CIT-话题@MedSci - 梅斯（MedSci）

#CIT#

176篇内容 | 3191人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1738452, encodeId=ded91e38452bf, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=A&R: 接受甲氨蝶呤治疗的类风湿关节炎患者合用Tofacitinib（CP-690,550）的临床随机研究, objectType=article, longId=17915, objectId=dbba1e915b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbba1e915b2, replyNumber=0, likeNumber=69, createdTime=2013-05-25, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbba1e915b2, moduleTitle=A&R: 接受甲氨蝶呤治疗的类风湿关节炎患者合用Tofacitinib（CP-690,550）的临床随机研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=dbba1e915b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738453, encodeId=63931e38453d5, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=CAFS 2013：Ensite Velocity系统在持续性房颤的消融治疗中的应用, objectType=article, longId=22458, objectId=b8642245899, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8642245899, replyNumber=0, likeNumber=67, createdTime=2014-04-15, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8642245899, moduleTitle=CAFS 2013：Ensite Velocity系统在持续性房颤的消融治疗中的应用, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b8642245899)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738454, encodeId=a97c1e3845423, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=礼来肺癌新药necitumumab III期试验改善总生存期, objectType=article, longId=23005, objectId=754e230053c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=754e230053c, replyNumber=0, likeNumber=81, createdTime=2013-12-19, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=754e230053c, moduleTitle=礼来肺癌新药necitumumab III期试验改善总生存期, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=754e230053c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738467, encodeId=6d601e384675d, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=CIT 2014预告：临床试验报告日程, objectType=article, longId=31993, objectId=c89a3199382, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c89a3199382, replyNumber=0, likeNumber=65, createdTime=2014-08-25, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c89a3199382, moduleTitle=CIT 2014预告：临床试验报告日程, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c89a3199382)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738455, encodeId=daf21e3845528, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=辉瑞潜在重磅药物tofacitinib 2个III期研究达主要终点, objectType=article, longId=25277, objectId=4107252e7fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4107252e7fd, replyNumber=0, likeNumber=46, createdTime=2013-12-21, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4107252e7fd, moduleTitle=辉瑞潜在重磅药物tofacitinib 2个III期研究达主要终点, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=4107252e7fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738449, encodeId=0e861e3844936, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=NEJM：新药Tofacitinib具有治疗类风湿性关节炎的疗效, objectType=article, longId=8928, objectId=d169892874, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d169892874, replyNumber=0, likeNumber=79, createdTime=2013-03-07, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d169892874, moduleTitle=NEJM：新药Tofacitinib具有治疗类风湿性关节炎的疗效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d169892874)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738448, encodeId=9c4c1e3844873, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=Capecitabine+Celecoxib：世界结肠直肠癌干细胞临床试验启动, objectType=article, longId=8080, objectId=7738808044, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7738808044, replyNumber=0, likeNumber=116, createdTime=2013-03-05, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7738808044, moduleTitle=Capecitabine+Celecoxib：世界结肠直肠癌干细胞临床试验启动, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=7738808044)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738444, encodeId=bd741e38444d7, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=CIT 2012：P值的意义在减少, objectType=article, longId=4447, objectId=59b4444e9e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59b4444e9e, replyNumber=0, likeNumber=72, createdTime=2013-03-11, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59b4444e9e, moduleTitle=CIT 2012：P值的意义在减少, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=59b4444e9e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738451, encodeId=f4861e38451e0, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=FDA批准tofacitinib治疗类风湿关节炎, objectType=article, longId=10908, objectId=07911090866, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=07911090866, replyNumber=0, likeNumber=64, createdTime=2013-01-05, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=07911090866, moduleTitle=FDA批准tofacitinib治疗类风湿关节炎, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=07911090866)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738450, encodeId=e6a31e3845017, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=引文分析软件histcite简介以及使用教程视频, objectType=article, longId=8958, objectId=be65895881, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be65895881, replyNumber=0, likeNumber=74, createdTime=2012-12-11, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be65895881, moduleTitle=引文分析软件histcite简介以及使用教程视频, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=be65895881)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738447, encodeId=86091e384476f, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=辉瑞潜在重磅药物tofacitinib下周面临FDA专家小组关键性表决, objectType=article, longId=5996, objectId=78a6599680, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=78a6599680, replyNumber=0, likeNumber=67, createdTime=2012-12-11, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=78a6599680, moduleTitle=辉瑞潜在重磅药物tofacitinib下周面临FDA专家小组关键性表决, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=78a6599680)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738446, encodeId=51c11e38446ec, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=[CIT2012]桡动脉能成为介入治疗的**吗？, objectType=article, longId=4820, objectId=e0de482029, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0de482029, replyNumber=0, likeNumber=70, createdTime=2012-04-19, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0de482029, moduleTitle=[CIT2012]桡动脉能成为介入治疗的**吗？, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e0de482029)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738445, encodeId=96dc1e3844540, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=高润霖院士谈CIT大会发展话介入成果, objectType=article, longId=4796, objectId=51cd4e9650, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=51cd4e9650, replyNumber=0, likeNumber=80, createdTime=2012-06-21, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=51cd4e9650, moduleTitle=高润霖院士谈CIT大会发展话介入成果, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=51cd4e9650)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738442, encodeId=2eaa1e384429d, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=CIT2012即将召开高润霖院士致辞, objectType=article, longId=4227, objectId=59a6422e32, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59a6422e32, replyNumber=0, likeNumber=84, createdTime=2012-08-08, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59a6422e32, moduleTitle=CIT2012即将召开高润霖院士致辞, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=59a6422e32)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738443, encodeId=597a1e38443ac, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=CIT：亚太心血管介入治疗全瞻, objectType=article, longId=4445, objectId=c0c34445ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c0c34445ea, replyNumber=0, likeNumber=87, createdTime=2013-02-25, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c0c34445ea, moduleTitle=CIT：亚太心血管介入治疗全瞻, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c0c34445ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738441, encodeId=c46c1e38441b5, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=CIT2011 主旨报告精粹, objectType=article, longId=2393, objectId=7f7d239316, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f7d239316, replyNumber=0, likeNumber=59, createdTime=2011-12-01, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f7d239316, moduleTitle=CIT2011 主旨报告精粹, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=7f7d239316)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CIT

2020-05-29

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

A&R: 接受甲氨蝶呤治疗的类风湿关节炎患者合用Tofacitinib（CP-690,550）的临床随机研究

2013-05-25

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

CAFS 2013：Ensite Velocity系统在持续性房颤的消融治疗中的应用

2014-04-15

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

礼来肺癌新药necitumumab III期试验改善总生存期

2013-12-19

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

CIT 2014预告：临床试验报告日程

2014-08-25

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

辉瑞潜在重磅药物tofacitinib 2个III期研究达主要终点

2013-12-21

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

NEJM：新药Tofacitinib具有治疗类风湿性关节炎的疗效

2013-03-07

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

Capecitabine+Celecoxib：世界结肠直肠癌干细胞临床试验启动

2013-03-05

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

CIT 2012：P值的意义在减少

2013-03-11

医者仁心 (审核中...)

前往app查看评论内容

#CIT#

FDA批准tofacitinib治疗类风湿关节炎

2013-01-05

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

引文分析软件histcite简介以及使用教程视频

2012-12-11

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

辉瑞潜在重磅药物tofacitinib下周面临FDA专家小组关键性表决

2012-12-11

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

[CIT2012]桡动脉能成为介入治疗的**吗？

2012-04-19

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

高润霖院士谈CIT大会发展话介入成果

2012-06-21

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

CIT2012即将召开高润霖院士致辞

2012-08-08

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

CIT：亚太心血管介入治疗全瞻

2013-02-25

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

CIT2011 主旨报告精粹

2011-12-01

科室
- - 订阅+
  - 更多科室
工具
服务